The exploration of the hub genes related to EGFR–TKI resistance in NSCLC through bioinformatics technologies can improve the understanding of the mechanisms of EGFR–TKI resistance and provide novel insights into therapeutics. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.